ADHDNCT06169709
An Online Survey for Women With Attention Deficit Hyperactivity Disorder (ADHD)
An observational study of ADHD, run by Parnassia Groep at 1 site in Netherlands.
Trial summary
The goal of this exploratory study following a cross-sectional online survey in women with ADHD is to 1. describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of support, and any perceived barriers on those domains; 2. determine which life domains are most affected by ADHD symptoms; 3. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- ADHD
- How many people
- 5,893 participants
- Where
- 1 siteNetherlands
- Study dates
- 20 Feb 2024to 10 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: The survey is aimed at women (or people who identify as women) over 18 years with ADHD (both self-diagnosed and diagnosed by a health professional).
Who may be able to join
- Identify as a woman
- Aged 18 or above
- Have ADHD (both diagnosed by a health professional and self-diagnosed)
Who cannot join
- People who are not able to read, understand, or sign the information letter or informed consent form are excluded from participation.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Diagnosis and Experiences From Women With ADHD; an International Survey
The goal of this exploratory study following a cross-sectional online survey in women with ADHD is to
- describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of support, and any perceived barriers on those domains;
- determine which life domains are most affected by ADHD symptoms;
- calculate the prevalence of reported health conditions within the following domains: circulatory system, endocrine or metabolic system, gastrointestinal system, genitourinary system, musculoskeletal system, nervous system, respiratory system, skin, reproductive system, cancer, psychiatric conditions, COVID-19, sensory sensitivity, menstrual cycle, and sleep;
- identify topics that women with ADHD would like to see studied in future research.
Read the detailed description
Rationale: In clinical practice, the investigators see that ADHD affects women differently than men. It has become clear that a better understanding of ADHD in girls and women is needed to improve their longer-term wellbeing and functional and clinical outcomes.
Objective: The primary endpoint is to describe the overall experience of women with ADHD regarding ADHD symptoms, diagnosis, treatment, and any perceived barriers relating to these domains. The investigators also want to determine the effects of ADHD symptoms on day-to-day life across various life domains. Moreover, the investigators want to determine the prevalence of reported health conditions.
Study design: This is an exploratory study following a cross-sectional online survey.
Study population: Women (aged >18 years) with ADHD.
Intervention (if applicable): Not applicable.
Main study parameters/endpoints: In women with ADHD, the investigators want to 1) describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of support, and any perceived barriers on those domains; 2) determine which life domains are most affected by ADHD symptoms; 3) calculate the prevalence of reported health conditions within the following domains: circulatory system, endocrine or metabolic system, gastrointestinal system, genitourinary system, musculoskeletal system, nervous system, respiratory system, skin, reproductive system, cancer, psychiatric conditions, COVID-19, sensory sensitivity, menstrual cycle, and sleep; 4) identify topics that women with ADHD would like to see studied in future research.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: This survey is the first to study experiences and health of women with ADHD internationally, and results will provide insights and leads for all involved with diagnosis and treatment of these women. Risks of participation are considered low. Participants might consider certain questions triggering, but are always free to skip questions and stop the survey.
- Conditions
- ADHD
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What is being measured
The primary outcome is the main question the study is designed to answer.
To describe the overall experiences, thoughts, and perspectives of women with ADHD, including domains of ADHD diagnosis and symptoms, ADHD and other health conditions, menstrual cycle, conflict tactics and romantic relationships, and sleep.
A self-developed questionnaire. The sections on demographic information, ADHD diagnosis, ADHD diagnosis \& symptoms and menstrual cycles are constructed for the purpose of this survey. Moreover, the questionnaire contains sections from the Ultrashort screener for adult ADHD, the Holland Sleep Disorder Questionnaire and the Conflict Tactics scale 2.
Measured: 50 minutes
Secondary outcomes (1)
To identify topics for further research and ways of improving healthcare (e.g. the diagnostic process or effective treatment) for women with ADHD
Questions are included in the questionnaire described for outcome 1.
Measured: 50 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2023
- Study start20 Feb 2024
- Primary completion10 Jul 2025
- Study completion10 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ADHDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 5,893 participants (actual)
Sponsor and investigators
- Lead sponsor
- Parnassia Groep
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Danielle de Graaf, Parnassia Groep
- Investigators
- Sandra Kooij, Prof. dr., Principal investigator, PsyQ
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06169709
- Sponsor's protocol ID
- Survey Female ADHD
- Status last verified
- Jul 2025
- First submitted
- 4 Dec 2023
- Last updated
- 18 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnosis and Experiences From Women With ADHD; an International Survey
- ClinicalTrials.gov ID
- NCT06169709
- Acronym / sponsor ID
- Survey Female ADHD
- Conditions
- ADHD
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,893 participants (actual)
- Lead sponsor
- Parnassia GroepUniversity, hospital or other
- Study start
- 20 Feb 2024 (actual)
- Primary completion
- 10 Jul 2025 (actual)
- Study completion
- 10 Jul 2025 (actual)
- First posted
- 13 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this exploratory study following a cross-sectional online survey in women with ADHD is to
- describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of support, and any perceived barriers on those domains;
- determine which life domains are most affected by ADHD symptoms;
- calculate the prevalence of reported health conditions within the following domains: circulatory system, endocrine or metabolic system, gastrointestinal system, genitourinary system, musculoskeletal system, nervous system, respiratory system, skin, reproductive system, cancer, psychiatric conditions, COVID-19, sensory sensitivity, menstrual cycle, and sleep;
- identify topics that women with ADHD would like to see studied in future research.
Detailed description
Rationale: In clinical practice, the investigators see that ADHD affects women differently than men. It has become clear that a better understanding of ADHD in girls and women is needed to improve their longer-term wellbeing and functional and clinical outcomes.
Objective: The primary endpoint is to describe the overall experience of women with ADHD regarding ADHD symptoms, diagnosis, treatment, and any perceived barriers relating to these domains. The investigators also want to determine the effects of ADHD symptoms on day-to-day life across various life domains. Moreover, the investigators want to determine the prevalence of reported health conditions.
Study design: This is an exploratory study following a cross-sectional online survey.
Study population: Women (aged >18 years) with ADHD.
Intervention (if applicable): Not applicable.
Main study parameters/endpoints: In women with ADHD, the investigators want to 1) describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of support, and any perceived barriers on those domains; 2) determine which life domains are most affected by ADHD symptoms; 3) calculate the prevalence of reported health conditions within the following domains: circulatory system, endocrine or metabolic system, gastrointestinal system, genitourinary system, musculoskeletal system, nervous system, respiratory system, skin, reproductive system, cancer, psychiatric conditions, COVID-19, sensory sensitivity, menstrual cycle, and sleep; 4) identify topics that women with ADHD would like to see studied in future research.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: This survey is the first to study experiences and health of women with ADHD internationally, and results will provide insights and leads for all involved with diagnosis and treatment of these women. Risks of participation are considered low. Participants might consider certain questions triggering, but are always free to skip questions and stop the survey.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The survey is aimed at women (or people who identify as women) over 18 years with ADHD (both self-diagnosed and diagnosed by a health professional).
Key inclusion criteria (3 listed)
- Identify as a woman
- Aged 18 or above
- Have ADHD (both diagnosed by a health professional and self-diagnosed)
Key exclusion criteria (1 listed)
- People who are not able to read, understand, or sign the information letter or informed consent form are excluded from participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To describe the overall experiences, thoughts, and perspectives of women with ADHD, including domains of ADHD diagnosis and symptoms, ADHD and other health conditions, menstrual cycle, conflict tactics and romantic relationships, and sleep.
Time frame: 50 minutes
A self-developed questionnaire. The sections on demographic information, ADHD diagnosis, ADHD diagnosis \& symptoms and menstrual cycles are constructed for the purpose of this survey. Moreover, the questionnaire contains sections from the Ultrashort screener for adult ADHD, the Holland Sleep Disorder Questionnaire and the Conflict Tactics scale 2.
1 secondary outcome
To identify topics for further research and ways of improving healthcare (e.g. the diagnostic process or effective treatment) for women with ADHD
Time frame: 50 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for ADHD
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sandra Kooij, Prof. dr. principal investigator
PsyQ
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ADHD, run by Parnassia Groep at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To describe the overall experiences, thoughts, and perspectives of women with ADHD, including domains of ADHD diagnosis and symptoms, ADHD and other health conditions, menstrual cycle, conflict tactics and romantic relationships, and sleep. (time frame: 50 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2025.